BioMérieux Reports Solid Third-Quarter Performance in 2024

bioMérieux, a leader in in vitro diagnostics, disclosed its third-quarter 2024 business results, highlighting a strong 11% organic sales growth in the quarter, reaching €969 million. For the first nine months, sales totaled €2,871 million, displaying a 10.3% organic growth. This growth was driven by the success of the GO•28 strategic plan, notably by a 12% increase in growth drivers and robust sales of BIOFIRE® panels.

The BIOFIRE® non-respiratory panels saw an 18% sales increase, and the SPOTFIRE® solution expanded with sales hitting €53 million. Microbiology and Industrial Applications also performed well, showing 9% sales growth. Regional sales increased significantly in the Americas with a 16% rise, supported by vigorous BIOFIRE® and SPOTFIRE® sales.

bioMérieux maintains confidence in meeting its upwardly revised 2024 targets, projecting 8% to 10% organic sales growth at constant exchange rates, despite a slight negative currency impact.